Abstract. The P75 neurotrophin receptor (p75 NTR ) is a cell surface receptor that can induce apoptosis in many cell types. This receptor plays a major role in the development of the central nervous system and is expressed in some adult brain cells. Its implication in cell apoptosis or survival is probably of major importance in cellular homeostasis and thus p75 NTR could be implicated in tumor resistance to death. In this study, we investigated the intracellular expression of p75 NTR in a human glioblastoma cell line. Detection of p75 NTR receptor in Golgi apparatus by immunofluorescence microscopy, or after Golgi apparatus extraction, could be correlated with a decrease of cell apoptosis leading cells to become tumorous. This hypothesis is supported by a loss of ligand-induced apoptosis in this cell line. Our observations show that p75 NTR can be sequestered in the Golgi complex and could then be, in part, responsible for the cell resistance to apoptosis and for brain tumor formation.
Introduction
The neurotrophins (NT) such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), NT-3 and -4, use a two receptor system to promote cell differentiation, survival or cell death by apoptosis. These receptors are the low affinity neurotrophin receptor p75 (p75 NTR ) and the tyrosine kinase receptor (Trk) family. Each NT is specific for a Trk receptor, but all bind the p75 NTR with comparable affinities (1) . P75
NTR is a glycoprotein that belongs to the tumor necrosis factor/nerve growth factor receptor family (TNFR/NGFR). This receptor is a type I transmembrane protein that contains an extracellular and an intracellular domain. The extracellular domain contains 4 repetitions of a 40-amino acid cysteine rich sequence, that can bind all of the four NTs, and a serinethreonine rich domain. The intracellular portion includes a death domain (2) and potential adaptator molecule-associated domains (3) . NT interaction with cystein-rich domain of p75 NTR induces different transduction pathways such as c-Jun N-terminal kinase (JNK) activation (4-6), sphingomyelin hydrolysis (7), nuclear transcription factor NF-κB activation (8) , caspase pathway activation (9, 10) , activation of cell cycle regulatory molecules (11, 12) and p53 activation (13) , leading to apoptosis, survival, differentiation or cell cycle regulation. P75 NTR is a glycoprotein of 75 kDa when all post-transductional modifications are added. Phosphorylation occurs on serine and threonine residues and may regulate receptor multimerization (14, 15) and palmitoylation happens on cysteine 279 (16) . Glycosylation of the receptor consists in a single asparagine-linked carbohydrate at position 33 located in the first cysteine repeat and several O-linked carbohydrates in the juxtamembrane stalk domain (17, 18) . These posttraductional modifications take place in endoplasmic reticulum and Golgi apparatus.
The Golgi apparatus is a series of flattened, cisternal membrane structures forming the heart of the secretory pathway. The Golgi stack is a polarized structure with a cis-face, the cis-Golgi network (CGN), exchanging proteins and lipids with the endoplasmic reticulum (ER), and a transface, the trans-Golgi network (TGN), communicating with the plasma membrane and compartments of the endocytic pathway. As secretory materials pass through the Golgi in a cis to trans fashion, it becomes post-translationally modified in a sequential order before being sorted at the TGN for delivery to its final destination within the cell (19) . P75 NTR isoforms have been detected. They are produced both by alternative splicing and proteolysis. One splice variant of p75 NTR consisted in only lost of the first cystein-rich repeat in its extracellular domain (20) . The splicing of the third exon of the p75 NTR transcript generated a variant that did not bind any of the NT because of the lack of cystein-rich domains 2, 3 and 4 but that could interfere with signaling transduction pathways. Full-length p75 NTR can also be cleaved by a constitutively active metalloproteinase to generate a soluble extracellular domain that is capable of binding neurotrophins and a receptor fragment containing the transmembrane and intracellular domains (21) (22) (23) . P75 NTR is a protein that is traditionally detected at the cell surface. Recently, involvement of p75 NTR in lipid rafts was shown and its contribution in signaling transduction confirmed (24) . Lipid rafts concentrate lipids and proteins that function in transmembrane signaling events, allowing them to interact with each other and preventing them for interacting with molecules excluded from rafts. We studied the expression of p75 NTR protein in the Golgi apparatus of U-87-MG cells and the effects of neurotrophin treatments on this localization. We also studied the consequence of this sequestration on the apoptosis induced by a specific p75 NTR ligand.
Materials and methods
Cell line culture. Human glioblastoma cells U-87 MG (ATCC, Manassas, VA) were cultured in MEM with Earl' salts (Gibco BRL, Cergy Pontoise, France) supplemented with 10% decomplemented fetal calf serum (FCS), 1.5 g/l sodium bicarbonate, 1% non-essential amino acids, sodium pyruvate (2 mM), penicillin (50 U/ml), streptomycin (50 U/ml), Lglutamine (2 mM) and fungizone (0.1%) (Gibco BRL). Cells were grown in a 25 cm 2 flask (Sarstedt, Orsay, France) at 37˚C in a humidified 5% CO 2 -95% air incubator. At sub-confluence, cells were recovered with versene (Gibco BRL) and cultured in Lab-Tek chamber slides at 10 4 cells per well for immunocytochemistry or in 96-well plates at 10 4 cells per well for apoptosis detection assays (Nunc, VWR, Strasbourg, France).
After 3 days in culture, different molecules were added prior to immunocytochemistry or functional assays: a human recombinant ß NGF (50 μM, ICN Biomedical, Irvine, CA), a human recombinant BDNF (50 μM, Promega, Charbonnières, France), a mouse anti-p75 NTR monoclonal antibody (anti-p75 mAb) without sodium azide (50 μM, clone NGFR5, NeoMarkers, Fremont, CA, USA) for 48 h, Brefeldin-A (BFA, 10 μg/ml, Sigma-Aldrich, Saint-Quentin Fallavier, France) for 2 h, or nordihydroguaiaretic acid (NDGA, 10 μM, Sigma-Aldrich) for 24 h. BFA is a fungal derived-substance known to cause apoptosis in different cell lines (25) by promoting retrogradous protein transport from the Golgi apparatus to the endoplasmic reticulum and that leads different components of Golgi complex to redistribute in a characteristic manner in all the cells (26) (27) (28) . NDGA, known as a dual inhibitor for lipooxygenases and cyclooxygenases, inhibits the transport assay but also causes disassembly of the Golgi apparatus (29) .
Immunofluorescence assays. In order to analyse receptors and ligands localisation, cell cultures were labeled at basal state or after exposure to BFA, NDGA, NGF or BDNF. Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) in PBS for 30 min at room temperature (RT) and permeabilized using alcool/acetone (v/v) for 5 min on ice. After a 90-min saturation at RT with 10% goat serum (Sigma-Aldrich) in PBS, cells were incubated for 90 min at RT with primary antibodies diluted in saturating solution: anti-p75 NTR monoclonal antibody, Lipid rafts were detected with a cholera toxin B subunit FITCconjugated (Sigma-Aldrich), incubated during 20 min at 4˚C, at 1/200 in PBS. Cells were fixed with glycerol gelatin (Sigma-Aldrich) and examined by confocal microscopy (Carl Zeiss S.A.S, LSM 510, Jena, Germany). Isotypic controls were realised using mouse IgG (Diaclone, Besançon, France) or rabbit Ig fraction (Dako Cytomation, Trappes, France).
Subcellular fractionation. Cells were washed twice in PBS and once in homogenization medium. After being resuspended in homogenization medium, cells were disrupted by 15 strokes in a Dounce homogenizer. Nuclei and unbroken cells were pelleted by centrifugation at 2000 g for 10 min. Discontinuous Iodixanol gradients were made according to Graham et al (31) with some modifications. Iodixanol was diluted to a final concentration of 50% Iodixanol, 0.25 M sucrose, 1 mM EDTA, and 10 mM HEPES, pH 7.4, as the gradient stock solution. Different densities of Iodixanol were established by diluting this stock with 0.25 M sucrose homogenization buffer. Gradients were then set up in 13 ml Beckman SW41 centrifuge tubes by underlayering with a syringe and metal needle as follows: 2.5% Iodixanol, 1 ml; 5%, 2 ml; 7.5%, 2 ml; 10%, 2 ml; 12.5%, 0.5 ml; 15%, 2 ml; 17.5%, 0.5 ml; 20%, 0.5 ml; and 30%, 0.3 ml. The vesicle fractions were loaded on top of the gradients and centrifuged in a SW41 rotor at 40,000 rpm for 2.5 h (4˚C). The resulting gradient was collected in 500 μl fractions. Iodixanol gradient material (OptiPrep, 60% w/v) was purchased from Sigma-Aldrich.
Fractions rich in Mannosidase II activity (32) (not shown), an enzyme selectively localized into Golgi vesicles, were centrifuged at 20,000 g for 30 min. The pellet obtained was resuspended in PBS with 0.25% Triton X-100.
Endoglycosidase digestion. Cells were washed once with PBS and lysed in appropriate buffer [PBS, 0.25% Triton X-100, 1 mM phenylmethylsulfoxyfluoride, 1 μg/ml aprotinin, 1 μg/ml pepstatin A, 1 μg/ml leupeptin, 1 mM NaF and 1 mM NaV 3 O 4 (Protease inhibitor cocktail set III, Calbiochem)]. After centrifugation at 14,000 g for 15 min at 4˚C, supernatants were collected. Protein concentrations were determined by the Bradford method (33) (Bio-Rad, Hercules, CA). After denaturation, deglycosylation of 100 μg of proteins was achieved by addition of 5 U of peptide-N-glycosidase F (EC 3.5.1.52, Sigma-Aldrich) or 0.04 U of O-glycosidase (EC 3.2.1.97, Sigma-Aldrich) and 1 U of neuraminidase (EC 3.2.1.18, Sigma-Aldrich), with adequate buffers, according to the manufacturer. Digests were incubated at 37˚C overnight.
Western blot analysis. Proteins (20 μg) were boiled for 5 min in Laemmli buffer, separated by electrophoresis on NuPAGE 4-12% Bis-Tris Gel (Invitrogen, Carlsbad, CA, USA) and transferred to nitrocellulose sheets (HAHY 0.45 μM, Millipore, St Quentin-Yvelines, France). After saturation with 5% non-fat dried milk in PBS, the sheets were incubated overnight at 4˚C with anti-p75 mAb (1/200, NGFR5) diluted in 1.5% bovine serum albumin (Jacques Boy Institute S.A., Reims, France) in PBS and with mouse IgG1 (Diaclone) as isotypic control. After three washes in PBS and a 1-h incubation with an anti-mouse Ig peroxidase-labelled goat antiserum (1/1 000, Dako Cytomation), the sheets were revealed by the Covalight enhanced chemiluminescence procedure (AbCys, Paris, France).
Flow cytometry analysis. Cells were released from the flask with versene, permeabilized or not with Triton X-100 for 5 min at 4˚C and resuspended in 10% FCS in versene with mouse anti-p75 NTR monoclonal antibody (NGFR5) diluted at 1/40 or mouse IgG1 Ig (Diaclone) as isotypic control. After a 30-min incubation on ice, antibodies were detected with a goat anti-mouse Ig FITC-conjugated antibody (Dako Cytomation) diluted at 1/100 in 10% FCS in versene during 30 min, on ice. Finally, cells were resuspended and fixed in 10% FCS/1% paraformaldehyde in versene.
Each analysis was performed on at least 20,000 cells and repeated thrice. Relative fluorescence intensity was measured by fluorescence-activated cell sorter analysis (Epics XLMCL Coulter, Hialeah, FL, USA). Mean fluorescence intensity (MFI) was the mean of the three independent experiments. anti-p75 NTR mAb, rate of apoptosis was measured using cell death detection ELISA plus according to the manufacturer's instructions. This method differentiates the late apoptotic and necrotic cells. This ELISA simultaneously uses two monoclonal antibodies against DNA and histones to allow the specific detection of mono-and oligo-nucleosomes in the cytoplasmic fraction, characteristic for apoptosis. Absorbance values were measured at 405 nm with ELISA reader (Packard Instruments, Meriden, USA). Results were from three independent experiments.
Terminal transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assays. After a 48-h stimulation, cultured cells were fixed with 4% paraformaldehyde diluted in PBS for 30 min at room temperature, permeabilized with 0.1% Triton X-100 during 5 min at 4˚C and stained by the TUNEL method with FITC labelling as described by the manufacturer (Promega) for 1 h at 37˚C. Reaction was stopped by a 10-min wash in salt sodium citrate 2X and cells were counterstained with Evans' blue (Sigma-Aldrich). Cells were counted by fluorescence microscopy (Carl Zeiss S.A.S) with a magnification x200 (a minimum of 600 cells from 3 fields were counted for each conditions). Each assay was repeated thrice. Statistical analysis was performed using the t-test. A p<0.05 was considered as statistically significant.
Results

P75
NTR protein is detected in Golgi apparatus. Immunocytochemical studies were performed with anti-p75 NTR antibodies on U-87 MG cells (Fig. 1A) . The p75
NTR receptor was detected in the Golgi apparatus as confirmed by double-staining with 
anti-p75
NTR mAb and anti-mannosidase II antibodies (antiGolgi Ab). The p75 NTR protein, near the nucleus, was detected with both anti-p75 NTR polyclonal antibodies, recognizing the N-terminsal part of the protein (anti-p75 NTR ntAb) and the C-terminus part (anti-p75 NTR ctAb). A p75 NTR cell surface labelling was also detected by immunocytochemistry (Fig. 1A) and confirmed by flow cytometry (Fig. 1B) , with the anti-p75 NTR mAb (clone NGFR5) on U-87 MG cells. While p75 NTR receptor was generally detected into the cells (MFI = 0.280±0.095, not detected when cells were not permeabilized), only 3% of U-87 MG cells expressed the p75 NTR receptor at cell surface (MFI = 41.9±5.8, Fig. 1B ). Isotypic control (in grey) was realised and superimposed with immunolabelling.
BFA and NDGA disrupt Golgi apparatus and p75
NTR labelling. Both molecules, BFA and NDGA, that degrade the Golgi apparatus disrupted Golgi and p75 NTR labelling in U-87 MG cell lines (Fig. 2) , confirming that the protein detected by the anti-p75 NTR antibodies was truly expressed in Golgi apparatus.
P75 NTR protein is not located in lipid rafts.
Anti-p75 NTR mAb and Raft double-stainings were performed on U-87 MG cell line, but no correlation could be observed, as no superimposable staining patterns were detected in cells expressing p75 NTR at cell surface (Fig. 3) .
The 75-kDa mature form of p75 NTR protein is present in Golgi apparatus. Molecular weights of proteins recognized by anti-p75 NTR antibody were analyzed by Western blotting on U-87 MG cell line (Fig. 4) . Different proteins were detected. Without enzymatic digestion (Fig. 4) , 75 and 53.4 kDa proteins were detected. A 56.6-kDa protein was occasionally detected (Fig. 4B) . Endoglycosidase digestions of the total cell lysate showed that the 75 kDa form of the protein is Nand O-glycosylated. The 56.6-kDa form appeared to be only N-glycosylated, whereas the 53.4-kDa form seemed to be neither O-nor N-glycosylated.
After Golgi apparatus extraction, Western blot analysis of proteins showed that the three forms of the p75 NTR protein were present in Golgi apparatus (Fig. 4B) . Isotypic controls were realized in order to verify non-specific labelling and no staining was observed (not shown).
Detection of TrkA, TrkB, NGF and BDNF in U-87 MG cells.
Immunocytochemical studies were performed with anti-TrkA, -TrkB, -NGF and -BDNF antibodies on U-87 MG cells (Fig. 5A ). TrkA and NGF were detected in the cells, whereas TrkB was also detected at cell membrane, and BDNF in Golgi apparatus (as confirmed by double-staining with anti-BDNF and anti-Golgin antibodies, see Fig. 5B ).
BDNF modifies the p75
NTR receptor cell surface expression. The U-87 MG cell line was treated with NGF and BDNF for 48 h. While NGF had no effect on p75 NTR protein localization in Golgi apparatus, BDNF changed its cell surface expression (Fig. 6A) . Indeed, p75
NTR protein quantity in cell extensions seemed to be increased when cells were observed by immunofluorescence (Fig. 6B) .
BDNF does not modify BDNF, TrkA and TrkB cell location.
The U-87 MG cell line was treated with BDNF for 48 h and double-staining immunocytochemicals studies were performed with anti-BDNF and anti-p75 NTR antibodies, or with anti-TrkA and anti-p75 NTR antibodies, or with anti-TrkB and and anti-p75 NTR antibodies (Fig. 7) . BDNF treatment had no effect on BDNF, TrkA and TrkB location, compared to basal. BDNF effect on p75 NTR cell surface expression decribed above was confirmed.
After BDNF treatment, p75
NTR protein is not co-localised with TrkB. After BDNF treatment, no correlation could be observed between p75 NTR and TrkB cell surface expression (Fig. 7C) .
Apoptosis detection of cell lines submitted to p75
NTR mAb treatments. The anti-p75 mAb (clone NGFR5) effect on the U-87 MG cell line was analysed by both TUNEL and cell death detection ELISA plus methods (Fig. 8) . Thus, whatever the method, no apoptosis variation was detected (p>0.3 for all comparisons).
Discussion
P75
NTR protein was usually detected at cell surface. In this report, this receptor has been localized in the Golgi apparatus of U-87 MG cells. Indeed, p75
NTR immunolabelling showed strong staining near the nucleus, suggesting that p75 NTR protein was localized in the Golgi apparatus. This hypothesis was confirmed by double-staining with both anti-p75 NTR and anti-Golgi antibody, as they stained the same area of cells. Furthermore, p75
NTR labelling was modified when cells were submitted to molecules that degrade Golgi apparatus, confirming that p75 NTR protein was truly localized in the Golgi apparatus. The use of polyclonal antibodies that recognized respectively p75 NTR N-and C-terminus domains, confirmed these results and suggested that p75 NTR is present in Golgi apparatus in it full length form. Nevertheless, some U-87 MG cells expressed p75 NTR at the cell surface, but at low rate. The analysis of p75 NTR molecular weight by Western blotting showed three main bands. Deglycosylation analysis demonstrates that the 53. to the N-glycosylated form and the 75 kDa to the mature receptor. Yeaman et al (34) showed that N-glycans are not necessary for sorting of p75 NTR at MDCK cell membrane, and that structural information for apical sorting of the receptor at membrane is localized to a juxtamembrane region of the extracellular domain that is rich in O-glycosylated serine/threonine residues. However, in our study, the mature O-glycosylated form of p75 NTR protein is localized in Golgi apparatus. Moreover, O-glycosylation was shown to be crucial for protein cell surface expression and may regulate association with rafts (35) . In contrast with this result, no clear relation between p75 NTR cell surface receptors and raft localization could be pointed out in U87-MG cells. As p75 NTR phosphorylation was described to be implicated in p75 NTR lipid raft localization (36) , it would be interesting to study p75 NTR phosphorylation in U87-MG cell line. Otherwise, the presence of O-glycosylations is a prerequisite for exit from the ER and protection from intracellular cleavage of p75 NTR (35) . The data are in accordance with the presence of the full length and O-glycosylated form of p75 NTR in Golgi complex of U87-MG cells, as demonstrated in our study.
The localization of the neurotrophins NGF and BDNF and their receptors, TrkA and TrkB, were studied in U-87 MG cells. Interestingly, as p75 NTR receptor, BDNF was detected in Golgi apparatus and could be the result of their internalization. Indeed, internalization of neurotrophins and their receptors are well documented. Kahle and Hertel (37) presented evidence that rat glial cells are able to sequester NGF from the cell surface to an intracellular compartment, and that p75 NTR may mediate this internalization. Moreover, Bronfman et al (38) showed a ligand-induced internalization of the p75 NTR receptor in PC12 cells. In their model, both internalized ligand and receptor were protected from proteolytic degradation and accumulated in vesicles that did not undergo acidification. Alderson et al (39) demonstrated that cultured hippocampal astrocytes and schwann cells specifically bind and internalize BDNF and NT-4/5. Moreover, they showed that a substantial portion of the endocytosed pool of neurotrophins is released back into the extracellular medium without obvious degradation. In retinal ganglion cells, NT-3, NGF and BDNF accumulate transiently in the Golgi system (40) . The NT-3 lysosomal pathway and the anterograde transport from Golgi apparatus involve binding to the p75 NTR receptor. Taken together, these data are consistent with the presence of BDNF and p75 NTR in the Golgi apparatus of U-87 MG cells, as demonstrated in our study. Since TrkB was present at U-87 MG cell surface as well as in the cytosol, this receptor could be involved in BDNF internalization.
Thus, in U-87 MG cells, p75 NTR protein is sequestered in the Golgi complex and not fully expressed at the cell surface. Like this receptor, two proteins belonging to the TNF receptor superfamily were reported to be detected in the Golgi apparatus. CD95 (Fas) membrane expression was shown to be regulated by sequestration in the Golgi complex in B-cell lymphoma (41) . Moreover, Bradley et al (42) showed that 55 kDa, but not 75 kDa, TNF receptors were predominantly localized in the Golgi apparatus of endothelial cells. As for Fas receptor, p75
NTR retention in the Golgi complex may therefore be an important mechanism for preventing p75 NTR cell surface expression in glial cells, which may be of direct relevance for brain tumor pathogenesis. This hypothesis seems to be confirmed by the fact that treatment with the anti-p75 NTR mAb did not increase the cell apoptotic rate of U-87 MG cells, while p75 NTR protein is reported to be a proapoptotic receptor in glioblastoma cell line (43, 44) . This receptor sequestration may be a way for tumor cells to escape from apoptosis due to neurotrophin binding. Thus, induction of p75 NTR expression on cell surface might be an interesting way to improve tumor apoptosis.
In order to study the effects of p75 NTR classical ligands, NGF and BDNF, we first tested the presence at cell surface of the neurotrophin receptors TrkA and TrkB in U-87 MG cells. The fact that NGF treatment did not change the expression pattern of p75 NTR is in accordance with the absence of TrkA at U-87 MG cell surface. However, BDNF treatment seemed to increase the p75 NTR receptor cell surface expression, which might be promoted by the presence of TrkB at cell surface. Bennett et al (45) showed that Fas is sequestered in Golgi apparatus of human vascular smooth muscle cells. Interestingly, p53 activation transiently increases Fas surface expression by transport from the Golgi complex. Moreover, p53-induced apoptosis of these cells requires surface transport of the receptor. Contrary to Fas which targets the cell surface during pro-apoptotic treatment in this model, p75
NTR in U-87 MG cells studied seemed here to require differentiation and proliferation factor (as BDNF) for targeting the cell surface. Thus, it would be of interest to submit U-87 MG cells to Fas-L treatment or other apoptosis inducing molecules, and to study eventual redistribution of p75 NTR . Considering that the decision of cell survival or death depends on the presence or absence of Trk receptors coexpressed with p75 NTR at cell surface (46), we looked for their eventual colocation after BDNF treatment: no correlation could be established between p75
NTR and TrkB or TrkA cell surface locations. Thus, whether this redistribution of p75 NTR at cell surface represents a pathway for differentiation, proliferation or death of U-87 MG cells remains to be clarified.
Intracellular sequestration of death receptors, like p75 NTR in U87-MG cells, may cause resistance to apoptosis and insensitivity to chemotherapeutic agents for cancer. Conversely, a therapy based on cell surface redistribution of death receptors through endogenous ligands remains to be studied, but also requires the understanding of the consequent signaling pathways.
